Short Interest in UCB SA (OTCMKTS:UCBJY) Grows By 668.9%

UCB SA (OTCMKTS:UCBJY) was the target of a large growth in short interest in the month of August. As of August 31st, there was short interest totaling 14,956 shares, a growth of 668.9% from the August 15th total of 1,945 shares. Based on an average daily volume of 67,990 shares, the days-to-cover ratio is presently 0.2 days. Approximately 0.0% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

UCBJY has been the subject of a number of research analyst reports. Jefferies Financial Group raised shares of UCB from a “moderate sell” rating to a “hold” rating in a report on Monday, August 3rd. Zacks Research raised shares of UCB from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 4th. Finally, Barclays lowered shares of UCB from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 15th. Two equities research analysts have rated the stock with a Strong Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy”.

UCB Price Performance

OTCMKTS:UCBJY opened at $119.35 on Friday. The company has a current ratio of 1.38, a quick ratio of 1.04 and a debt-to-equity ratio of 0.20. UCB has a 12 month low of $114.53 and a 12 month high of $168.76. The business’s 50-day moving average is $130.83 and its 200 day moving average is $141.17.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on developing and commercializing medicines for people living with severe neurological and immunological diseases. The company operates internationally, serving patients and healthcare providers across North America, Europe and other global markets.

Its neurology portfolio includes treatments such as Keppra and Briviact for epilepsy, Vimpat for partial-onset seizures and Fintepla for certain severe seizure disorders. In immunology, UCB markets Cimzia for conditions including rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis and Crohn’s disease, as well as Bimzelx for several inflammatory skin and joint conditions.

UCB traces its origins to 1928, when it was established in Belgium as Union Chimique Belge.